Poll: Investors 'More Likely' to Buy ETFs Amid Volatile Market
Source: etf.com poll
A large number—39%—said that the market's down days aren't impacting their decision to buy, suggesting that many investors are staying the course in their portfolios.
Current market volatility could prove a buying opportunity. Legendary investor Warren Buffett—the Oracle of Omaha—once famously said to get greedy when others are fearful. The ProShares VIX Short-Term Futures ETF (VIXY) has jumped more than 16% over the past month as broad market funds have remained under pressure.
VIXY tracks the CBOE Volatility Index (VIX), also known as the market's "fear gauge."
Last week, the S&P 500 had its worst trading week since September. The SPDR S&P 500 ETF Trust (SPY) dropped more than 3% from the prior Friday. Investors pulled $3.8 billion from the fund during that same time. Over the past month, the fund's performance has dipped by more than 4% as trade war fatigue and the back-and-forth on tariffs have caused markets to whipsaw.
Despite poll respondents showing that they're more interested in investing in ETFs during market turbulence, fund flows data show that investors at scale haven't yet followed suit.
Total market flows for last week totaled just $11.7 billion, according to etf.com data. The numbers are a large step down from the week prior when investors poured $49.6 billion into ETFs. While investors added more than $4.5 billion to equity ETFs last week, fixed-income ETFs raked in nearly $7.8 billion as uncertainty in the markets caused investors to turn away from risk.
The iShares 20+ Year Treasury Bond ETF (TLT) pulled in the most out of any fund on Friday, bringing in just over $1 billion.Permalink | © Copyright 2025 etf.com. All rights reserved
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
These 3 investing mistakes can put your retirement at risk
Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below. After nearly seven decades of experience, investing legend Warren Buffett has accumulated more than $142 billion in personal wealth — and the Oracle of Omaha believes much of his success is based on his ability to avoid losing money. Buffett has always advocated a long term investment approach — which is perhaps the reason why his strategies resonate with millions of people. Don't miss Thanks to Jeff Bezos, you can now become a landlord for as little as $100 — and no, you don't have to deal with tenants or fix freezers. Here's how I'm 49 years old and have nothing saved for retirement — what should I do? Don't panic. Here are 6 of the easiest ways you can catch up (and fast) Want an extra $1,300,000 when you retire? Dave Ramsey says this 7-step plan 'works every single time' to kill debt, get rich in America — and that 'anyone' can do it 'You only have to do a very few things right in your life so long as you don't do too many things wrong,' he once said. With that in mind, here are 3 investment mistakes Buffett says you should avoid in order to secure your fortune for the long term. 1. Speculating instead of investing Some investors fail to recognize the difference between a speculative asset and an investment-worthy asset. According to Buffett, the difference is in how the asset generates a return. 'All investment is laying out some money now to get more money back in the future,' Buffett once explained. 'Now, there's two ways of looking at getting the money back. One is from what the asset itself will produce. That's investment. [The other] is from what somebody else will pay you for it later on, irrespective of what the asset produces. And I call that speculation.' Buffett believes that assets that produce income organically — such as farmland, profitable companies, dividend stocks and real estate investment trusts — are investment-worthy. You can build your own circle of competency with trusted advisors who bring their expertise on growing wealth — and can help you find a financial professional that's right for you. is a free online platform that connects you with vetted financial advisors. Just answer a few quick questions about yourself and your finances, and the platform will match you with experienced financial professionals best suited to help you develop a plan to achieve your financial goals. You can view the advisors' profiles, read past client reviews, and schedule an initial consultation for free with no obligation to hire. There is also an accessible family office option for established investors with larger portfolios. 2. Trying to time the market Market timing is tempting but deceptive. Investors often convince themselves they can wait for the right time to buy or sell a stock. However, experienced investors understand that market cycles are unpredictable, so staying invested for longer is typically the best approach. "You shouldn't buy stocks unless you expect to hold them for a very extended period and you are prepared financially and psychologically to hold them," Buffett had said during Berkshire Hathaway's annual meeting in 2020. If you are investing for retirement, you need to make sure you are picking the right stocks. Also, you need to make sure you are planning correctly to meet your short-term goals without having to cash out your portfolio. You can get a shortcut for understanding which stocks are worth buying and holding with Moby. Their superior research can help you reduce the guesswork when selecting stocks and ETFs. With easy-to-understand formats, their team of former hedge fund analysts and experts demystifies the stock market, so you can become a wiser investor in just five minutes. In four years, across almost 400 stock picks, Moby's recommendations have beaten the S&P 500 by almost 12%, on average. Read more: Nervous about the stock market? Gain potential quarterly income through this $1B private real estate fund — even if you're not a millionaire. 3. Hedging against volatility Real estate has historically been less speculative than stocks, with stable returns generating a steady stream of passive income. It is often touted as one of the best avenues to build wealth — a move that can pay off brilliantly for your retirement. However, with home prices steadily increasing over the past few years, direct ownership of residential real estate might be challenging. But that doesn't mean you can't tap into the $30 trillion home equity market, with real estate crowdfunding companies that let you invest in residential properties without constantly worrying about mortgage or home maintenance expenses. For those who prefer accessible fractional investing, Arrived — an online platform backed by prominent investors like Jeff Bezos — offers retail investors the opportunity to buy shares in existing rental and vacation homes. You can get your foot into the real estate market without buying property outright. With Arrived, you can browse a curated selection of homes, each vetted for their appreciation and income potential. Once you find a property you like, you can choose the number of shares you want to buy and start investing in real estate with just $100. A recent report from Cushman & Wakefield also commented, 'for the first time in years, the retail market is at a point of being supply-constrained — at least for space in quality shopping centers." With both commercial and residential supply constrained, rental prices could be pushed higher, creating attractive returns for investors. For accredited investors looking to expand their portfolios and make a larger allocation, First National Realty Partners (FNRP) offers accredited investors access to retail-anchored real estate investments, without the legwork of finding deals yourself. The FNRP team has developed relationships with shopping centers and health-care facilities across the U.S., as well as the nation's largest essential-needs brands, including Kroger, Walmart and Whole Foods. They also offer white-glove service for investors, providing key market insights and finding the best properties both on and off-market, while investors can passively collect distribution income. You can engage with experts, explore available deals and easily make an allocation, all in one personalized secure portal. To truly accelerate your net worth, consider getting expert guidance across all areas of your wealth. That's where the trusted team of financial planners at Range can come in. For high-earning professionals or households making over $200,000, Range offers a smart, streamlined way to manage your full financial life — especially your real estate investments. Through a strategic partnership with Engineered Tax Services, Range members receive free cost segmentation analysis and discounted cost segmentation studies. Range advisors will then use the study as part of a member's tax planning and strategy. Cost segmentation shortens depreciation timelines — from the standard 27.5–39 years down to just 5–15 years—allowing you to claim significantly larger tax deductions sooner and keep more money in your pocket. Note that only investment properties qualify for segmentation studies. Range also delivers proactive advice across your entire financial life — not just real estate or taxes From stock options and tax strategies to real estate and big-picture planning, Range integrates it all under one roof. With a transparent, flat annual fee — no hidden costs or percentage-of-assets surprises — you get AI-powered insights and comprehensive guidance designed to scale with your wealth. What to read next Robert Kiyosaki warns of a 'Greater Depression' coming to the US — with millions of Americans going poor. But he says these 2 'easy-money' assets will bring in 'great wealth'. How to get in now Here are 5 simple ways to grow rich with real estate if you don't want to play landlord. And you can even start with as little as $10 Rich, young Americans are ditching the stormy stock market — here are the alternative assets they're banking on instead Here are 5 'must have' items that Americans (almost) always overpay for — and very quickly regret. How many are hurting you? Stay in the know. Join 200,000+ readers and get the best of Moneywise sent straight to your inbox every week for free. This article provides information only and should not be construed as advice. It is provided without warranty of any kind. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool Sign in to access your portfolio
Business Insider
2 hours ago
- Business Insider
Seeking Up to 11% Dividend Yield? Analysts Pick 2 Dividend Stocks to Buy
The stock markets hit a low in April, and have since shown a tremendous rebound – but can it last? That's the question investors are wrestling with now, and it seems they are getting some pointers from Barry Bannister, chief equity strategist at Stifel. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Bannister believes that the stock rebound – fueled by the AI boom, and the rush of capital spending as companies moved to get ahead of tariffs during the first half of the year – is simply not sustainable, noting that the S&P 500 is trading at a historically high valuation. 'Valuation doesn't matter until it does,' Bannister says, and adds that he can see the S&P 500 index falling as low as 5,500, for a drop of nearly 15%. Despite this downbeat outlook, Bannister is not recommending that investors get out of the market. He's recommending, instead, that investors make defensive moves to seek protection from a turndown. That outlook will naturally push investors' attention toward high-yield dividend stocks. These represent the classic defensive play, and for good reason. Dividends offer investors a steady income stream, and high-yield dividends guarantee a sound return well above the rate of inflation. Against this backdrop, we've opened up the TipRanks database to take a look at two dividend stocks that the analysts are picking out as Buys. These are dividend stocks offering yields as high as 11%, a solid return by any standard. Let's give them a closer look. Ellington Financial (EFC) The first stock we'll look at here, Ellington Financial, is a REIT, a real estate investment trust. These companies operate through strategic investments, mainly in real properties, mortgages, and mortgage-related assets, in both the residential and commercial spheres. Ellington's particular strategy involves building a diverse investment portfolio, made up of both residential and commercial mortgage loans, along with residential and commercial mortgage-backed securities, as well as other assets, including consumer loans, collateralized loan obligations, and various mortgage-related and non-mortgage-related securities and derivatives. Ellington's main goal in building this portfolio is to generate returns for its stockholders – in the company's words, 'attractive risk-adjusted total returns.' Ellington's strategy is opportunistic, targeting remunerative investments, but the company takes a defensive posture as well, investing across a wide range of sectors to capitalize on disparate strengths in its portfolio and making risk management a key part of its activities. As of June 30 this year, Ellington Financial had a total of $16.1 billion in assets under management. This portfolio is managed by an experienced team – the company's portfolio managers average 30 years of industry experience. These features of Ellington's business, its focus on shareholder returns and the long experience of its management team, have helped the company to cement a reputation as a high-quality dividend payer. The company's dividend features a high yield, as well as a monthly payment schedule. The last declaration, made on August 7 for a September 30 payment, was for 13 cents per common share. That dividend annualizes to $1.56 per share and gives a powerful forward yield of 11.5%. In its 2Q25 financial report, Ellington listed its quarterly adjusted distributable earnings as $45 million, or 47 cents per share. This was more than enough to fully cover the dividend, which currently comes to 39 cents per quarter. Covering this stock for Piper Sandler, following the Q2 print, analyst Crispin Love laid out a clear case for investors to go long on EFC: 'Ellington posted a beat this quarter with strength in both its credit and Longbridge strategies. In April around the market volatility, Ellington saw opportunities to deploy capital in its core credit strategies and also saw attractive opportunities in securities. Following the volatility, EFC was able to complete six securitizations in the quarter, which is a record for the company. The company also experienced success from its loan originator platforms, and we would not be surprised to see more partnerships and equity stakes over the intermediate term. Specifically, if there is GSE reform it could limit Fannie and Freddie's footprint and provide opportunities for Ellington to grow further in the non-QM space which is an area of expertise. Management was positive on the forward earnings trajectory and continued coverage of the $0.39 dividend.' These comments back up Love's Overweight (i.e., Buy) rating, and his $14.50 price target implies a gain of 5.5% in the next 12 months. But with the dividend yield included the upside can reach 17%. (To watch Love's track record, click here) There are 7 recent analyst reviews on record for Ellington, and the 5-to-2 split, favoring Buys over Holds, supports a Moderate Buy consensus rating. The Street's average target of $14.25 is the same as Love's. (See EFC stock forecast) LPG) Our world runs on energy, and the next company on our list here, Dorian LPG, is a leading carrier of that energy. Dorian is an owner/operator of very large gas carriers, VLGC vessels, which are the largest ocean-going carriers of liquefied petroleum gas, an important fuel in the world economy. The core of Dorian's business is its fleet of ships. The company maintains a modern fleet of VLGCs, with the oldest ship dating back to 2007. Most of the company's vessels were launched much more recently, in 2015, and the newest vessels in the fleet were launched in 2023. The vessels have an average age of 8 years, and their aggregate carrying capacity is some 2.1 million cubic meters of LPG. Dorian owns 21 of its ships, and operates the others on charter agreements. Most of the ships in Dorian's fleet are flagged in the Bahamas, although several are flagged in Liberia, Madeira, or Panama. The company is headquartered in Connecticut and has offices in Copenhagen and Athens. The international office footprint, and varying flags, are also common on the world's oceangoing cargo carriers. Dorian finished its last quarter, fiscal 1Q26 (June quarter), with just over $278 million in cash and liquid assets. The company pays an irregular dividend, meaning it has no obligation to pay out, or to maintain dividend payments at any level; while this poses risks for investors, it also allows the company to adjust the dividend to keep them affordable. That said, Dorian has been paying out dividends since 2021, and has not missed a quarterly payment in that time. The most recent dividend, declared on August 1 for payment on the 27th, set the rate at 60 cents per share. This dividend annualizes to $2.40 per common share, and gives a forward yield of 8%. On the financial side, Dorian generated $84.2 million in total revenues during its fiscal first quarter, a total that was down 26% year-over-year and fell shy of analyst expectations by $2.3 million. Additionally, adj. EPS of $0.27 missed the Street's forecast by $0.34. Despite the weak report, Jefferies analyst Omar Nokta remains bullish on the stock, writing: 'Dorian reported softer than expected fiscal 1Q26 results mainly due to higher G&A and higher drydocking costs, and also slightly lower than expected revenues… We view this earnings miss as a one-off… VLGC spot rates have strengthened materially and are at 2025 highs, setting up a very strong upcoming result next quarter and potentially a higher dividend… The company remains dedicated to returning capital to shareholders, and its shares trade at a discount to our NAV valuation of $33.80/sh… Dorian is our top pick in the LPG space, and we remain constructive on the name.' The 5-star analyst rates LPG shares as a Buy, and gives them a price target of $35, pointing toward a one-year gain of 16.5%. (To watch Nokta's track record, click here) There are only 2 recent analyst reviews on file for Dorian, but both are positive, giving the stock its Moderate Buy consensus rating. The shares are priced at $30.06, and the $33 average price target implies a 10% upside potential on the one-year horizon. (See LPG stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
